The development status of the next-generation immune checkpoint inhibitors.
Recently immune checkpoint inhibitors such as anti-CTLA-4, PD-1 and PD-L1 blocking antibodies have been developed resulting in the dramatic change of standard-of-care in can- cer treatment. Furthermore, in phase 3 study of nivolumab plus ipilimumab for metastatic malignant melanoma, the combination therapy prolonged progression-free survival and im- proved objective response rate, showing the promising activity of the combination therapy with immune checkpoint inhibitors. On the other hand, the frequencies of immune related adverse events increased. Now new immune checkpoint inhibitor is expected to develop so as to substitute for these or to be used with combination. Here we will address the mecha- nism and the function of Lag-3, TIGIT and Tim-3 that are expected as immune checkpoint inhibitors.